MAZE revenueQ2 2026$0
- QoQ
- -100.0%
MAZE revenue was $0 in fiscal Q2 2026 (ended Jun 30, 2026), compared with $0 a year earlier and down 100.0% from the prior quarter. For the full fiscal 2024 it was $167.50M.
Maze Therapeutics Inc. (MAZE) financials
For the twelve months ended Jun 30, 2026, Maze Therapeutics Inc. reported -$133.59M of net income.
- Net income, TTM
- -$133.59M
- Free cash flow, TTM
- -$106.84M
- Cash
- $202.64M
- Total debt
- $38.96M
- Market cap
- $1.90B
FY2024FY2025
FY2024FY2025
MAZE revenue and earnings growth
MAZE net incomeQ2 2026-$44.73M
MAZE net income was -$44.73M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$33.68M a year earlier. For the full fiscal 2025 it was -$131.12M, compared with $52.23M in fiscal 2024.
MAZE EPSQ2 2026-$0.76
MAZE diluted EPS was -$0.76 in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$0.77 a year earlier. For the full fiscal 2025 it was -$3.05.
MAZE free cash flowQ2 2026-$15.16M
MAZE free cash flow was -$15.16M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$30.45M a year earlier. For the full fiscal 2025 it was -$112.73M, compared with $74.81M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 |
|---|---|---|
| Revenue | - | $167.50M |
| Research and development | $108.45M | $83.50M |
| Selling, general and admin | $34.45M | $26.42M |
| Operating income | -$142.90M | $57.59M |
| Pre-tax income | -$131.12M | $53.40M |
| Income tax | $0 | $1.17M |
| Net income | -$131.12M | $52.23M |
| EPS, basic | -$3.05 | $1.42 |
| EPS, diluted | -$3.05 | $1.25 |
| Diluted shares | 43.0M | 2.7M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 |
|---|---|---|
| Cash and equivalents | $189.25M | $197.90M |
| Short-term investments | $152.67M | - |
| Current assets | $349.72M | $201.67M |
| Total assets | $397.13M | $240.54M |
| Current liabilities | $22.56M | $20.67M |
| Total liabilities | $42.16M | $43.64M |
| Shareholders' equity | $354.97M | -$311.18M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 |
|---|---|---|
| Operating cash flow | -$111.94M | $75.95M |
| Capital expenditures | $794.0K | $1.15M |
| Free cash flow | -$112.73M | $74.81M |
| Investing cash flow | -$170.96M | -$1.15M |
| Financing cash flow | $275.34M | $92.85M |
| Stock-based compensation | $16.40M | $9.65M |
Key ratios
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $20.00M | - | - | $0 | $0 | $0 | $2.50M | $165.00M | $0 |
| Research and development | $34.94M | $34.15M | $27.57M | $25.19M | $28.11M | $27.58M | $22.22M | $19.86M | $19.55M | $21.88M |
| Selling, general and admin | $13.10M | $12.40M | $10.49M | $7.78M | $8.37M | $7.82M | $7.51M | $6.87M | $5.90M | $6.14M |
| Operating income | -$48.03M | -$26.55M | -$38.06M | -$32.97M | -$36.47M | -$35.40M | -$29.73M | -$24.23M | $139.56M | -$28.01M |
| Interest expense | $931.0K | $866.0K | - | - | - | - | - | - | - | - |
| Pre-tax income | - | - | -$34.57M | -$30.09M | -$33.68M | -$32.79M | -$29.85M | -$25.03M | $140.78M | -$32.49M |
| Income tax | - | - | $0 | $0 | $0 | $0 | -$275.0K | -$279.0K | $1.73M | $0 |
| Net income | -$44.73M | -$24.21M | -$34.57M | -$30.09M | -$33.68M | -$32.79M | -$29.58M | -$24.75M | $139.06M | -$32.49M |
| EPS, basic | -$0.76 | -$0.45 | - | -$0.66 | -$0.77 | -$1.15 | - | -$10.25 | $5.92 | -$13.91 |
| EPS, diluted | -$0.76 | -$0.45 | - | -$0.66 | -$0.77 | -$1.15 | - | -$10.25 | $3.22 | -$13.91 |
| Diluted shares | 59.0M | 53.9M | - | 45.8M | 43.8M | 28.6M | - | 2.4M | 4.3M | 2.3M |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $202.64M | $198.77M | $189.25M | $316.77M | $264.54M | $294.37M | $197.90M | $149.61M | $175.06M | $30.02M |
| Short-term investments | $208.44M | $153.62M | $152.67M | $67.16M | - | - | - | - | - | - |
| Receivables | - | $20.00M | - | - | - | - | - | - | - | - |
| Current assets | $420.42M | $379.78M | $349.72M | $391.30M | $271.15M | $299.71M | $201.67M | - | - | - |
| Total assets | $531.63M | $419.71M | $397.13M | $422.06M | $303.52M | $332.84M | $240.54M | - | - | - |
| Current liabilities | $22.96M | $21.24M | $22.56M | $22.11M | $19.90M | $18.62M | $20.67M | - | - | - |
| Short-term debt | $0 | $0 | - | - | - | - | - | - | - | - |
| Long-term debt | $38.96M | $38.83M | - | - | - | - | - | - | - | - |
| Total debt | $38.96M | $38.83M | - | - | - | - | - | - | - | - |
| Total liabilities | $78.50M | $78.01M | $42.16M | $42.62M | $41.28M | $40.77M | $43.64M | - | - | - |
| Shareholders' equity | $453.12M | $341.70M | $354.97M | $379.44M | $262.24M | $292.07M | -$311.18M | -$284.53M | -$262.37M | -$403.66M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$15.05M | -$39.11M | -$27.73M | -$24.64M | -$30.05M | -$29.52M | -$22.45M | -$23.20M | $145.05M | -$23.44M |
| Capital expenditures | $107.0K | $93.0K | $34.0K | $68.0K | $393.0K | $299.0K | $605.0K | $103.0K | $160.0K | $279.0K |
| Free cash flow | -$15.16M | -$39.21M | -$27.76M | -$24.71M | -$30.45M | -$29.82M | -$23.06M | -$23.31M | $144.89M | -$23.72M |
| Investing cash flow | -$128.51M | $6.28M | -$103.39M | -$66.88M | -$393.0K | -$299.0K | -$605.0K | -$103.0K | -$160.0K | -$279.0K |
| Financing cash flow | $147.44M | $42.36M | $3.59M | $143.76M | $612.0K | $127.38M | $70.26M | -$2.15M | $154.0K | $24.58M |
| Stock-based compensation | $9.19M | $7.11M | $6.07M | $3.86M | $3.24M | $3.23M | $2.85M | $2.34M | $2.14M | $2.31M |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | - | - | - | - | -100.0% | - | - | - | - | - |
| Operating margin | - | -132.8% | - | - | - | - | - | -969.2% | 84.6% | - |
| Net margin | - | -121.0% | - | - | - | - | - | -990.1% | 84.3% | - |
| Free cash flow margin | - | -196.0% | - | - | - | - | - | -932.3% | 87.8% | - |
| Current ratio | 18.31 | 17.88 | 15.50 | 17.70 | 13.63 | 16.10 | 9.76 | - | - | - |
| Debt to equity | 0.09 | 0.11 | - | - | - | - | - | - | - | - |
Source: XBRL data Maze Therapeutics Inc. files with the SEC, latest filing dated Aug 11, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
MAZE peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| MAZE | - | - | -$133.59M | - | $1.90B |
| AMGN | $38.90B | +8.2% | $9.39B | 24.1% | $249.05B |
| GILD | $30.99B | +6.5% | -$3.86B | -12.5% | $207.00B |
| MRNA | $2.52B | +13.1% | -$2.79B | -110.5% | $101.48B |
| ARGX | $4.25B | +88.6% | $1.29B | 30.4% | $57.55B |
| RVMD | $0 | - | -$1.13B | - | $41.59B |
| BIIB | $10.30B | +2.3% | $347.50M | 3.4% | $36.71B |
| BNTX | €2.87B | +4.3% | -€1.14B | -39.6% | $21.98B |
| EXEL | $2.50B | +9.1% | $885.14M | 35.5% | $16.98B |
MAZE FAQ
5 questionsIs MAZE profitable?
No. Maze Therapeutics Inc. reported a net loss of $133.59M for the twelve months ended Jun 30, 2026.How much cash and debt does MAZE have?
Maze Therapeutics Inc. reported $202.64M in cash and cash equivalents and $38.96M of debt on its most recent balance sheet in SEC filings.What is MAZE free cash flow?
Maze Therapeutics Inc. generated -$106.84M of free cash flow for the twelve months ended Jun 30, 2026, which is operating cash flow of -$106.54M less capital expenditures.When did MAZE last report financial results?
The latest statements here come from Maze Therapeutics Inc.'s 10-Q filed on Aug 11, 2026, covering the period ended Jun 30, 2026.Where does this MAZE financial data come from?
Quantisnow builds these statements from the structured XBRL data Maze Therapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.